

ASX ANNOUNCEMENT

CELLMID PRESENTS FGF5 INHIBITOR DATA AT WORLD CONGRESS FOR HAIR RESEARCH

- **Clinical study data on FGF5 inhibitors preventing hair loss will be presented**
- **Prominent plenary session to the entire congress audience**
- **Poster will also be presented on discovery of novel FGF5 inhibitors**

SYDNEY: Tuesday, 31 October 2017, Cellmid Limited (ASX: CDY) is pleased to advise that the Company will be presenting the recently published FGF5 inhibitor clinical data at the World Congress for Hair Research (WCHR) in Kyoto, Japan. The meeting, which is in its tenth year, is the pre-eminent forum for hair biology research and is attended by more than 700 leading international scientists and clinicians.

In a prominent plenary session Advangen scientist, Dr Dominic Burg, will be presenting the results of the recently published clinical study describing the efficacy of the FGF5 inhibiting évolis® tonic formulation. The talk, which is one of only two plenaries at the WCHR, will be given on the first day and in front of the entire congress, making it one of the most significant presentations during the three days of proceedings.

The plenary will describe key findings of the recently published clinical study which demonstrated that topical use of évolis® was effective against hair loss in men and women. Over 16 weeks of treatment évolis®:

- Reduced hair loss by 82%;
- Increased the rate of actively growing hair follicles by 44% and
- Improved hair density.

A second abstract on the Company's FGF5 technology will be presented as a scientific poster and will describe Advangen's *in vitro* pipelines for active compound discovery. It will include analysis on the newly identified single molecule FGF5 inhibitors, which shows up to seven times more efficacy than Advangen's original plant extracts.


The World Congress for Hair Research is the preeminent scientific meeting for hair science, organised by several international organisations including The Society for Hair Science Research and the North American Hair Research Society. The congress is attended by more than 700 hair biologists, dermatologists, cosmetic scientists and hair transplantation surgeons from over 50 countries.

The presentation of results on the use of Advangen's FGF5 inhibiting topical formulation to such an internationally recognised expert audience will provide an excellent avenue for exposure of the Company's technology, compelling clinical data and products.

End

Contact: Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel target midkine (MK). Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, the USA and Japan, and currently broadening distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited - Cellmid's Consumer Health Division

In 2013 Cellmid acquired Advangen Inc. (Japan), the owner of a range of FGF5 hair growth technologies and became the first, and still the only, company globally with an FGF5 inhibitor hair growth product range on the market. Cellmid has continued innovation and product development and filed a number of new patent applications covering several hair growth agents including midkine and a group of novel FGF5 inhibitors. In addition to distribution in Australia, The USA and Japan the Company is actively expanding into other markets including Asia and Europe.

Investment in life sciences companies

There are many inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.